BEAM
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam\'s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Beam Therapeutics Inc. (BEAM) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D-). The rating has held at C for 8 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (2.9) | D- (0.9) | C (2.3) | C (2.5) | C+ (2.6) | C (2.2) |
| 2026-11-10 | B- (2.9) | D- (1.0) | C (2.3) | C+ (2.8) | C+ (2.6) | C (2.3) |
| 2026-11-03 | B- (2.9) | D (1.3) | C (2.3) | C (2.5) | C+ (2.7) | C (2.3) |
| 2026-10-27 | B- (2.9) | D (1.4) | C (2.3) | C (2.2) | C+ (2.6) | C (2.3) |
| 2026-10-20 | B- (2.9) | D (1.5) | C (2.3) | C (2.2) | C+ (2.6) | C (2.3) |